These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 11690559

  • 1. Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer.
    Shain SA.
    Mol Urol; 2001; 5(3):121-30. PubMed ID: 11690559
    [Abstract] [Full Text] [Related]

  • 2. Endogenous fibroblast growth factor-1 or fibroblast growth factor-2 modulate prostate cancer cell proliferation.
    Shain SA, Sarić T, Ke LD, Nannen D, Yoas S.
    Cell Growth Differ; 1996 May; 7(5):573-86. PubMed ID: 8732667
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
    Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Iozzo RV, Garaci E, Cozzolino F, Torcia MG.
    Prostate; 2002 Dec 01; 53(4):310-21. PubMed ID: 12430142
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
    Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB.
    Cancer Res; 2003 Nov 01; 63(21):7365-76. PubMed ID: 14612535
    [Abstract] [Full Text] [Related]

  • 11. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.
    Heer R, Robson CN, Shenton BK, Leung HY.
    J Cell Physiol; 2007 Sep 01; 212(3):572-8. PubMed ID: 17541959
    [Abstract] [Full Text] [Related]

  • 12. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.
    Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757
    [Abstract] [Full Text] [Related]

  • 13. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1997 Aug 01; 138(8):3290-8. PubMed ID: 9231780
    [Abstract] [Full Text] [Related]

  • 14. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z.
    Prostate; 2006 Mar 01; 66(4):413-20. PubMed ID: 16302272
    [Abstract] [Full Text] [Related]

  • 15. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
    Ye D, Mendelsohn J, Fan Z.
    Clin Cancer Res; 1999 Aug 01; 5(8):2171-7. PubMed ID: 10473102
    [Abstract] [Full Text] [Related]

  • 16. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 17. Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen.
    Huot RI, Shain SA.
    Cancer Res; 1986 Aug 15; 46(8):3775-81. PubMed ID: 2942235
    [Abstract] [Full Text] [Related]

  • 18. Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies.
    Lin H, Lu JP, Laflamme P, Qiao S, Shayegan B, Bryskin I, Monardo L, Wilson BC, Singh G, Pinthus JH.
    Int J Oncol; 2010 Oct 15; 37(4):761-6. PubMed ID: 20811696
    [Abstract] [Full Text] [Related]

  • 19. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 20. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor.
    Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C.
    Endocrinology; 1997 Apr 15; 138(4):1406-12. PubMed ID: 9075695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.